Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Doug Schenkel
Period: Reporting period mapped to calendar 2026 Q3.
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 2 companies
DHRDanaher Corporation2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2026 Q3
as you sit here today, what is foundational, and how do you think about evolving the playbook?
Show response
Julie kept the operating company structure and DBS but committed to a more connected Danaher, commercial focus and share gain; direct.
What operating or financial metrics should investors use to assess progress pursuant to that top priority?
Show response
Named commercial excellence as the near-term lever and core growth plus share gain as the scorecard; cited Diagnostics connected selling wins; direct.
TMOThermo Fisher Scientific2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2026 Q3
the key investments you've made during the tools downturn that position Thermo to disproportionately benefit
Show response
Pointed to the innovation cadence, Pharma Services and clinical research investment, bioproduction capacity, and the filtration and Clario acquisitions.
could this potentially drive actually an increase to your long-term company organic growth algorithm?
Show response
Said 7% is not a cap and AI-enabled medicines should support the long term, without committing to a higher growth algorithm.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| DHR Danaher Corporation | 2 | —Rate withheld: fewer than 3 questions |
| TMO Thermo Fisher Scientific | 2 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2026 Q3 | 4 | 0%none of 4 questions | 2 |
- 2026 Q34 questions · challenge rate 0% (none of 4 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Competitive Dynamics2
- Revenue Growth2
- Capex Investment1
- Innovation & R&D1
- M&A1
- Cloud & AI1